- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 12
- States / cities
- Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Traumatic Brain Injury
- Interventions
- Ovidrel, Placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Brivekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Northridge, California + 14 more
- Conditions
- Asthma
- Interventions
- MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
- Conditions
- Multiple Myeloma
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
- Conditions
- IgA Nephropathy
- Interventions
- Telitacicept 160mg, Telitacicept 240mg, Placebo
- Drug
- Lead sponsor
- RemeGen Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
- Conditions
- Eosinophilic Gastritis or Gastroenteritis
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Melanoma, Metastases
- Interventions
- MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,783 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 110
- States / cities
- Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- Remternetug, Matching Placebo (Remternetug)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2034
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
- Conditions
- Cluster Headache
- Interventions
- Fremanezumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
- Conditions
- Atopic Dermatitis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Lupus Erythematosus Arthritis
- Interventions
- Methylprednisolone, Placebos
- Drug
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide, Phosphate Buffer Saline (PBS),
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Wheaton, Maryland
- Conditions
- Treatment-Resistant Depression
- Interventions
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • San Antonio, Texas
- Conditions
- Pain
- Interventions
- Intravenous acetominophen, Ketorolac, intramuscular, Bupivacaine, subcutaneous, Normal saline
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- HIV, HIV Lipodystrophy
- Interventions
- tesamorelin, placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Diseases
- Interventions
- COR-001, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Male Idiopathic Infertility
- Interventions
- FE 999049, Placebo
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Tempe, Arizona • San Jose, California • Centennial, Colorado + 10 more
- Conditions
- Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 31 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SAR425899, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Baton Rouge, Louisiana
- Conditions
- Hepatitis C
- Interventions
- BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more